Part of the weekly research here at The Acquirer’s Multiple features some of the top picks from our Stock Screeners and some top investors who are holding these same picks in their portfolios. Investors such as Warren Buffett, Joel Greenblatt, Carl Icahn, Jim Simons, Prem Watsa, Jeremy Grantham, Seth Klarman, Ray Dalio, and Howard Marks. The top investor data is provided from their latest 13F’s. This week we’ll take a look at:
Biogen IDEC Inc (NASDAQ: BIIB)
Biogen and Idec merged in 2003, combining forces to market Biogen’s multiple sclerosis drug Avonex and Idec’s cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen’s MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.
A quick look at the price chart below for Biogen shows us that the stock is down 32% in the past twelve months. We currently have the stock trading on an Acquirer’s Multiple of 6.57 which means that it remains undervalued.
(Source: Morningstar)
Superinvestors who currently hold positions in Biogen include:
Cliff Asness – 3,793,752 total shares
Jim Simons – 2,483,077 total shares
Ray Dalio – 248,933 total shares
Joel Greenblatt – 155,286 total shares
Ken Fisher – 119,970 total shares
Paul Tudor Jones – 33,437 total shares
Ken Griffin – 15,109 total shares
For all the latest news and podcasts, join our free newsletter here.
Don’t forget to check out our FREE Large Cap 1000 – Stock Screener, here at The Acquirer’s Multiple:
